RP Bio Inc. (KOSDAQ:314140)
South Korea · Delayed Price · Currency is KRW 5,760.00
+150.00 (2.67%)
At close: May 29, 2026
RP Bio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 137,354 | 136,219 | 123,967 | 151,046 | 138,109 | 114,964 |
Other Revenue | -0 | -0 | - | -0 | -0 | -0 |
| 137,354 | 136,219 | 123,967 | 151,046 | 138,109 | 114,964 | |
Revenue Growth (YoY) | 9.47% | 9.88% | -17.93% | 9.37% | 20.13% | 17.40% |
Cost of Revenue | 123,008 | 122,407 | 116,783 | 135,487 | 120,355 | 102,052 |
Gross Profit | 14,346 | 13,812 | 7,184 | 15,560 | 17,754 | 12,912 |
Selling, General & Admin | 7,021 | 7,192 | 6,509 | 7,678 | 7,109 | 6,036 |
Amortization of Goodwill & Intangibles | 22.13 | 18.11 | 5.81 | 25.07 | 75.14 | 76.27 |
Other Operating Expenses | 430.45 | 426.63 | 538.68 | 533.92 | 447.05 | 410.13 |
Operating Expenses | 8,644 | 8,728 | 7,878 | 8,937 | 8,107 | 7,032 |
Operating Income | 5,702 | 5,084 | -693.64 | 6,623 | 9,647 | 5,880 |
Interest Expense | -705.27 | -829.23 | -1,251 | -1,796 | -1,184 | -979.22 |
Interest & Investment Income | 512.75 | 525.99 | 521.51 | 703.69 | 316.79 | 165.63 |
Currency Exchange Gain (Loss) | -8.35 | -26.67 | -1.04 | -11.69 | -29.51 | -1.84 |
Other Non Operating Income (Expenses) | 236.36 | 54.55 | 216.48 | 198.12 | -3,232 | -769.29 |
EBT Excluding Unusual Items | 5,738 | 4,808 | -1,208 | 5,717 | 5,519 | 4,295 |
Gain (Loss) on Sale of Investments | 1.59 | 1.59 | - | - | - | - |
Gain (Loss) on Sale of Assets | -178.59 | -178.59 | -9.24 | -59.74 | 150.06 | -4.31 |
Pretax Income | 5,561 | 4,631 | -1,217 | 5,658 | 5,669 | 4,291 |
Income Tax Expense | -42.03 | -50.91 | -309.88 | 220.38 | 1,353 | 478.26 |
Net Income | 5,603 | 4,682 | -907.12 | 5,437 | 4,316 | 3,813 |
Net Income to Common | 5,603 | 4,682 | -907.12 | 5,437 | 4,316 | 3,813 |
Net Income Growth | 328.65% | - | - | 25.99% | 13.20% | -17.40% |
Shares Outstanding (Basic) | 9 | 9 | 9 | 9 | 7 | 7 |
Shares Outstanding (Diluted) | 9 | 9 | 9 | 9 | 7 | 7 |
Shares Change (YoY) | 0.10% | 0.12% | -7.53% | 31.19% | 8.34% | -1.16% |
EPS (Basic) | 647.53 | 541.31 | -105.00 | 630.00 | 617.00 | 580.00 |
EPS (Diluted) | 647.53 | 541.31 | -105.00 | 582.00 | 606.00 | 580.00 |
EPS Growth | 328.23% | - | - | -3.96% | 4.48% | -16.43% |
Free Cash Flow | 12,645 | 7,276 | 7,670 | -543.31 | -3,992 | 2,213 |
Free Cash Flow Per Share | 1461.47 | 841.15 | 887.85 | -58.16 | -560.54 | 336.69 |
Gross Margin | 10.44% | 10.14% | 5.79% | 10.30% | 12.86% | 11.23% |
Operating Margin | 4.15% | 3.73% | -0.56% | 4.38% | 6.98% | 5.12% |
Profit Margin | 4.08% | 3.44% | -0.73% | 3.60% | 3.13% | 3.32% |
Free Cash Flow Margin | 9.21% | 5.34% | 6.19% | -0.36% | -2.89% | 1.93% |
EBITDA | 12,012 | 11,495 | 6,124 | 12,671 | 15,050 | 11,083 |
EBITDA Margin | 8.74% | 8.44% | 4.94% | 8.39% | 10.90% | 9.64% |
D&A For EBITDA | 6,310 | 6,412 | 6,818 | 6,048 | 5,403 | 5,203 |
EBIT | 5,702 | 5,084 | -693.64 | 6,623 | 9,647 | 5,880 |
EBIT Margin | 4.15% | 3.73% | -0.56% | 4.38% | 6.98% | 5.12% |
Effective Tax Rate | - | - | - | 3.90% | 23.87% | 11.15% |
Advertising Expenses | - | 128.83 | 80.7 | 225.5 | 230.56 | 135.92 |